---
layout: default
title: Regorafenib
parent: 僅模型預測 (L5)
nav_order: 63
evidence_level: L5
indication_count: 8
---

# Regorafenib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **8** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# REGORAFENIB: Repurposing Evaluation — Insufficient Data to Complete Full Assessment

---

## One-Sentence Summary

REGORAFENIB (DrugBank ID: DB08896) is a drug for which the current Evidence Pack contains **no approved indication records, no mechanism of action data, and no TxGNN-predicted indications**.
A complete repurposing evaluation cannot be generated at this time; the report below documents what is available and specifies the remediation steps required before moving forward.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current data |
| Predicted New Indication | No predictions returned |
| TxGNN Prediction Score | Not available |
| Evidence Level | Below L5 — no predictions or studies linked |
| Germany Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No predicted indications were returned by the TxGNN pipeline for this candidate (`predicted_indications: []`).
Without a target indication to evaluate, a mechanistic rationale cannot be constructed.

Additionally, the mechanism of action (MOA) field is flagged as a data gap (DG002, severity: High).
Without MOA information, it is not possible to reason about pharmacological plausibility even if a candidate indication were proposed.

**What is needed before this section can be written:**
1. Re-run the TxGNN model to confirm whether prediction output was suppressed due to a pipeline error or genuinely returned no candidates above threshold.
2. Retrieve MOA data from DrugBank (DG002 remediation: query DrugBank API for DB08896).

---

## Clinical Trial Evidence

Currently no related clinical trials registered for the predicted indication — no target indication is available.

---

## Literature Evidence

Currently no related literature available — no target indication is available.

---

## Germany Market Information

REGORAFENIB has **0 authorizations** in the current regulatory dataset. No product listings are available to display.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** Two blocking data gaps prevent safety assessment:
> - **DG001 (Blocking):** Package insert warnings and contraindications have not been parsed. Remediation: download the PDF from the official regulatory authority and extract the text.
> - **DG002 (High):** MOA data is absent, which prevents DDI mechanistic analysis. Remediation: query the DrugBank API for DB08896.

No drug interaction data was found (DDI query status: `not_found`, 0 interactions).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for REGORAFENIB is critically incomplete — there are no predicted indications, no approved indication text, no MOA, and no safety data available for evaluation. Proceeding without these inputs would produce an unreliable assessment.

**To proceed, the following is needed:**

- [ ] **Diagnose TxGNN pipeline** — Confirm whether the empty `predicted_indications` array reflects a genuine below-threshold result or a pipeline failure (e.g., missing graph embedding for DB08896).
- [ ] **Retrieve MOA from DrugBank API** — Query DB08896 to obtain pharmacology, mechanism of action, and drug categories (resolves DG002).
- [ ] **Parse package insert** — Download and extract warnings, contraindications, and approved indications from the regulatory authority PDF (resolves DG001).
- [ ] **Re-run Evidence Pack generation** — After filling DG001 and DG002, regenerate the Evidence Pack (v5 or later) and resubmit for report generation.
- [ ] **Confirm target indication** — Once TxGNN predictions are available, select the top-ranked indication and retrieve linked clinical trials and literature via the evidence pipeline.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

